Arcus Biosciences, Inc.

NYSE:RCUS 株式レポート

時価総額:US$1.4b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Arcus Biosciences マネジメント

マネジメント 基準チェック /24

Arcus Biosciences'の CEO はTerry Rosenで、 May2015年に任命され、 の在任期間は 9.08年です。 の年間総報酬は$ 10.12Mで、 6.4%給与と93.6%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.31%を直接所有しており、その価値は$ 4.56M 。経営陣と取締役会の平均在任期間はそれぞれ3.8年と4.3年です。

主要情報

Terry Rosen

最高経営責任者

US$10.1m

報酬総額

CEO給与比率6.4%
CEO在任期間9.1yrs
CEOの所有権4.1%
経営陣の平均在職期間3.8yrs
取締役会の平均在任期間4.3yrs

経営陣の近況

Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31
Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

Recent updates

Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31
Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO

May 15

Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

May 13
Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

May 10
Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

Mar 20
We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Feb 23
What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment

Feb 22

Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Dec 18
Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Arcus Biosciences: Showing There Might Be Something To TIGIT After All

Dec 15

Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Nov 30
Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey

Nov 20

Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data

Aug 29

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Aug 08
Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates

Jun 15

Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

May 05
Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17

Nov 02

Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers

May 12
Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers

Arcus Biosciences: Not Much Data Yet, But Gilead Deal Is A Huge Value Add

Jan 07

Forecast: Analysts Think Arcus Biosciences, Inc.'s (NYSE:RCUS) Business Prospects Have Improved Drastically

Nov 25
Forecast: Analysts Think Arcus Biosciences, Inc.'s (NYSE:RCUS) Business Prospects Have Improved Drastically

CEO報酬分析

Arcus Biosciences の収益と比較して、Terry Rosen の報酬はどのように変化したか?
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$231m

Dec 31 2023US$10mUS$650k

-US$307m

Sep 30 2023n/an/a

-US$293m

Jun 30 2023n/an/a

-US$287m

Mar 31 2023n/an/a

-US$279m

Dec 31 2022US$9mUS$350k

-US$267m

Sep 30 2022n/an/a

US$80m

Jun 30 2022n/an/a

US$67m

Mar 31 2022n/an/a

US$58m

Dec 31 2021US$9mUS$367k

US$53m

Sep 30 2021n/an/a

-US$278m

Jun 30 2021n/an/a

-US$199m

Mar 31 2021n/an/a

-US$168m

Dec 31 2020US$6mUS$326k

-US$123m

Sep 30 2020n/an/a

-US$88m

Jun 30 2020n/an/a

-US$112m

Mar 31 2020n/an/a

-US$95m

Dec 31 2019US$2mUS$340k

-US$85m

Sep 30 2019n/an/a

-US$80m

Jun 30 2019n/an/a

-US$69m

Mar 31 2019n/an/a

-US$54m

Dec 31 2018US$1mUS$295k

-US$50m

Sep 30 2018n/an/a

-US$51m

Jun 30 2018n/an/a

-US$63m

Mar 31 2018n/an/a

-US$59m

Dec 31 2017US$427kUS$315k

-US$53m

報酬と市場: Terryの 総報酬 ($USD 10.12M ) は、 US市場 ($USD 5.66M ) の同規模の企業の平均を上回っています。

報酬と収益: Terryの報酬は増加しましたが、会社は利益を上げていません。


CEO(最高経営責任者

Terry Rosen (64 yo)

9.1yrs

在職期間

US$10,120,945

報酬

Dr. Terry J. Rosen, Ph D., serves as Director at PACT Pharma, Inc. He co-founded Arcus Biosciences, Inc. in 2015 and has been its Chief Executive Officer since May 2015. Dr. Rosen has been the Chairman of...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Terry Rosen
Co-Founder9.1yrsUS$10.12m4.1%
$ 59.1m
Juan Jaen
Co- Founder & President9.1yrsUS$4.75m1.57%
$ 22.6m
Robert Goeltz
Principal Financial Officer & CFO3.8yrsUS$3.59m0.017%
$ 244.6k
Jennifer Jarrett
Chief Operating Officer3.7yrsUS$4.74m0.069%
$ 998.6k
Dimitry Nuyten
Chief Medical Officer1.8yrsUS$3.69m0.015%
$ 218.7k
K. Christopher Garcia
Co-Founder & Member of Scientific Advisory Boardno dataデータなしデータなし
Alexander Azoy
VP of Finance & Principal Accounting Officer1.3yrsデータなし0.0032%
$ 46.8k
Jonathan Yingling
Chief Scientific Officer3.4yrsデータなしデータなし
Carolyn Tang
General Counsel & Corporate Secretary5.8yrsUS$2.92m0.053%
$ 758.3k
Holli Kolkey
Vice President of Corporate Communicationsno dataデータなしデータなし
Yvonne Gehring
Senior Vice President of Human Resources & Operationsno dataデータなしデータなし
Eric Matthews
Chief Commercial Officer5yrsデータなしデータなし

3.8yrs

平均在職期間

52yo

平均年齢

経験豊富な経営陣: RCUSの経営陣は 経験豊富 であると考えられます ( 3.8年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Terry Rosen
Co-Founder9.2yrsUS$10.12m4.1%
$ 59.1m
K. Christopher Garcia
Co-Founder & Member of Scientific Advisory Boardno dataデータなしデータなし
Yasunori Kaneko
Lead Independent Director9.1yrsUS$503.21k0.16%
$ 2.3m
Kathryn Falberg
Independent Director6.8yrsUS$479.08k0.16%
$ 2.4m
Andrew Perlman
Independent Director3.5yrsUS$455.83k0.023%
$ 331.3k
Jeffrey Bluestone
Chairman of Scientific Advisory Boardno dataデータなしデータなし
C. Machado
Independent Director4.5yrsUS$455.83k0.019%
$ 267.5k
David Lacey
Independent Director & Member of Scientific Advisory Board4.1yrsUS$500.83k0.054%
$ 779.6k
Antoni Ribas
Independent Director & Member of Scientific Advisory Board9.4yrsUS$470.83k0.034%
$ 482.9k
Merdad Parsey
Director3.9yrsデータなしデータなし
Nicole Lambert
Independent Director2.8yrsUS$450.83k0.015%
$ 222.2k
Stefani Spranger
Member of Scientific Advisory Board3.8yrsデータなしデータなし

4.3yrs

平均在職期間

63.5yo

平均年齢

経験豊富なボード: RCUSの 取締役会経験豊富 であると考えられます ( 4.3年の平均在任期間)。